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The purpose of this study is to validate the recently pub-
lished Breast–Graded Prognostic Assessment (GPA) and
propose a new prognostic model and nomogram for pa-
tients with brain parenchymal metastases (BM) from
breast cancer (BC). We retrospectively investigated 171
consecutive patients who received a diagnosis of BM
from BC during 2000–2008. We appraised the recently
proposed Sperduto’s BC-specific GPA in training cohort
through Kaplan-Meier survival curve using log-rank test
and area under the curve for the BC-GPA predicting
overall survival at 1 year and developed a new nomogram
to predict outcomes using multivariate Cox-regression
analysis. By putting the Sperduto’s Breast-GPA together
with our nomogram, we developed a new prognostic
model. We validated our new prognostic model with an
independent external patient cohort from 2 institutes for
the same period. On the basis of our Cox-regression anal-
ysis, therapeutic effect of trastuzumab and status of extra-
cranial systemic disease control were incorporated into
our new prognostic model in addition to Karnofsky
performance status, age, and hormonal status. Our
new prognostic model showed significant discrimination
in median survival time, with 3.7 months for class I (n5
15), 7.8 months for class II (n 5 82), 10.7 months for
class III (n 5 42), and 19.2 months for class IV (n 5 32;
P < .0001). The new prognostic model accurately pre-
dicted survival among patients with BC from BM in
an external validation cohort (P < .0001). We propose
a new prognostic model and a nomogram reflecting the
different biological features of BC, including treatment
effect and status of extracranial disease control, which
was excellently validated in an independent external
cohort.
Keywords: brain metastasis, breast cancer, HER2,
prognosis, trastuzumab.
B
reast cancer (BC) is the second-most frequent
cause of brain metastases (BM) after lung cancer.
BM in patients with metastatic breast cancer
(MBC) occurs in 10%–16% of patients, approaching
30% when autopsy diagnosis of BM is included.1,2 BM
generally tends to occur during the late stage of MBC.3
The prognosis of patients who develop BM from BC is
generally poor, and the median survival is 6–7 months
(range, 2–16 months), with only approximately 20%
of patients reaching 1 year of survival.4–6
Treatment decisions must take into account clinical
prognostic factors to maximize survival and neurologic
function while avoiding unnecessary treatment. Consi-
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dering that several multimodal treatments including cor-
ticosteroids, whole brain radiotherapy (WBRT), surgery
or stereotactic radiosurgery (SRS), and/or systemic che-
motherapy have been used in an unorganized fashion, it
is crucial to predict prognosis accurately and to deter-
mine the most appropriate treatment modality in pa-
tients with BM. The most widely accepted prognostic
index for patients with BM has been the recursive parti-
tion analysis (RPA), based on the database of 1200 pa-
tients of 3 consecutive Radiation Therapy Oncology
Group (RTOG) trials.7 They originally proposed 3
classes with different outcomes according to age, perfor-
mance status, and extracranial primary tumor control,7
with a median survival of 7.1 months for class I, 4.2
months for class II, and 2.3 months for class III. Since
then, new prognostic scores have been developed
through several modifications,8–10 such as the score
index for radiosurgery (SIR),9,11 basic score for brain
metastases (BSBM),10 and graded prognostic assessment
(GPA).8
Although several prognostic indexes have been devel-
oped, they are based on populations with BM from a
combination of various primary cancers. In the original
RPA proposed by Gaspar et al.,7 most of the patients had
primary lung cancer, and patients with BC comprised
,15% of the study population. Very few patients with
BM from BC can be categorized in class I, but many pa-
tients survive beyond class II/III estimates in this RPA
index system. Therefore, it remains uncertain whether
the RPA classification can be safely applied to patients
with BM from BC. Although a BC-specific GPA was
first proposed by Sperduto et al.,12 biological features ac-
cording to intrinsic subtypes of BC were not fully consid-
ered. It has been reported that BC subtypes are
associated with unique patterns of metastatic spread,
with notable differences in survival after relapse.13–16
In this context, a recently proposed BC-specific GPA re-
flecting biological subtype is a valuable tool to predict
prognosis and decide further treatment options.17
The progressive neurologic disabilities both impair
the quality of life and decrease survival; thus, the
control of CNS lesion(s) is very important for overall
disease control. However, survival depends on both in-
tracranial disease control and extracranial systemic
disease control. Causes of death in patients with BC
with BM are different according to subtypes; approxi-
mately half of HER2-positive patients with BM die of
CNS progression, whereas patients with triple-negative
BC (TNBC) with BM rarely die due to CNS progression
alone. Most cases of TNBC do not seem to respond well
to systemic treatment, with the poorest survival among
BC subtypes,5 and progression in extracranial systemic
disease not in CNS lesion(s) is the dominant cause of
morbidity and mortality. Therefore, extracranial system-
ic disease control is one of the most important factors for
predicting outcomes. However, control of extracranial
systemic disease was not a statistically significant
factor in Sperduto’s prognostic model system.
Systemic therapy after WBRT has been known to signif-
icantly improve survival among patients with HR-positive
and/or HER2-positive BC. According to retrospective
analysis reported by Dawood et al. that compared the
prognosis among 3 groups of patients, women with meta-
static HER2-positive BC with and without the addition of
trastuzumab with women with HER2-negative disease,
trastuzumab has beneficially changed the natural history
of HER2-positive BC and improved the survival time
among women with HER2-positive tumors beyond those
of women with HER2-negative disease.18 In addition,
the survival time among the patients with HER2-positive
BC after BM could be prolonged with the use of
anti-HER2 agents, such as trastuzumab, through extracra-
nial systemic disease control.19,20
In the present study, we tried to validate the recently
refined BC-specific GPA in our cohort, and then we de-
veloped a nomogram to comprehensively reflect tumor
and host characteristics of BM from BC. Then, we pro-
posed a new prognostic index model with a better pre-
diction of survival among patients with BC with BM.
Materials and Methods
Patients and Methods
We retrospectively analyzed the medical records of 171
consecutive patients who received a diagnosis of BM
from BC during 2000–2008 at Samsung Medical
Center (SMC). All patients had histologically confirmed
adenocarcinoma of the breast in the primary and/or
metastatic site(s). All pathologic specimens were re-
viewed by 2 experienced pathologists who determined
the primary tumor characteristics based on histologic
and nuclear grades, tumor size, presence of lymphovas-
cular invasion (LVI), multiplicity, axillary nodal status,
and the status of immunohistochemical (IHC) staining
for receptors (estrogen receptor [ER], progesterone recep-
tor [PgR], and human epidermal growth factor receptor-2
[HER2]). ER and PgR positivity was defined as Allred
scores within the range of 3–8 by IHC using antibodies
to ER (Immunotech) and PgR (Novocastra), respectively.
HER2 status was evaluated using an antibody (DAKO)
and/or fluorescence in situ hybridization (FISH).
Grades 0 and 1 for HER2 by IHC were defined as a neg-
ative result and grade 3 as a positive result. Amplification
of HER2 was confirmed by FISH if HER2 was rated 2+
by IHC. Triple negativity was defined as a lack of ER,
PgR, and HER2 expressions.
Treatment modalities for brain parenchymal metasta-
ses included symptomatic management with corticoste-
roids, WBRT, surgical resection, SRS, and systemic
treatment (chemotherapy, hormonal therapy, and tras-
tuzumab) or a combination of these modalities.
Sperduto’s Breast-GPA score was calculated as the
sum of each score, which included KPS, ER/PgR,
HER2 status, and age. We tried to validate the
Sperduto’s score system using our patient cohorts.
Then, we developed a nomogram to accurately predict
patient outcome based on the multivariate Cox-
regression model based on dichotomized variables.
Using our nomogram, we developed a new prognostic
model and validated it with an external patient cohort.
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Our study protocol was approved by the institutional
review board of SMC.
For external validation of the models, we used an in-
dependent external cohort that included 199 patients
with BM from BC treated at Severance Hospital of
Yonsei University and Asan Medical Center from
January 2004 through June 2009.
Statistical Analysis
The overall survival from BM (BM-OS) was defined
from the date of BM to death or the last follow-up
date. BM-OS was estimated using the Kaplan-Meier
method. The log-rank test was used to compare survival
rates. A cutoff P value of .05 was adopted for all statis-
tical analyses. Statistical data were generated using the
SPSS software package (SPSS/PASW, version 18.0).
Receiver-operating characteristic (ROC) curves were
drawn using the MedCalc software system (version
12.2.1.0). For constructing the nomogram, the open-
source statistical language and platform, R, version
2.12.1 (R Development Core Team, 2010), with the
package rms (version 3.1-1) was used (http://CRAN.
R-project.org/package=rms).
The following data were analyzed in terms of BM-OS
by log-rank test in univariate analysis: age, performance
status, hormonal receptor status with HER2 expression
profile, extracranial disease status at the time of diagno-
sis of BM, number of brain lesion(s), recursive partition-
ing analysis (RPA) class at the time of BM, treatment
modalities such as brain surgery, WBRT, SRS, and sys-
temic treatments including trastuzumab use. Then, the
variables that were identified as risk factors in univariate
analysis were examined using multivariate analysis with
Cox-regression model. Differences were considered as
statistically significant when P , .05.
A Cox proportional hazards regression model was
used to assess the effect of each potential prognostic var-
iable on BM-OS. All potential prognostic variables were
included in the model, and variables were then removed
from this model one at a time in a backward selection
process using the likelihood ratio test and a significance
level of .05.
To develop a well-calibrated and exportable nomo-
gram for BM-OS, we used the Cox-regression model.
The nomogram performance was quantified with
respect to discrimination and calibration. Moreover,
we used the bootstrapping method (1000 repetitions)
to obtain relatively unbiased estimates of model perfor-
mance. Discrimination was quantified with the AUC.
We performed the calibration using graphic representa-
tions of the relationship between the observed outcome
frequency and the predicted probability.
The ROC curve was drawn for the 1-year survival
probability of all 171 patients in the nomogram. The
power of the nomogram score was evaluated using the
AUC with a 95% confidence interval (CI). The sensitiv-
ity and specificity were calculated for the nomogram
score cutoff value to predict 1-year survival among all
171 patients. Then, ROC curves were drawn for the
199 patients of the external validation set.
Results
Patient Cohorts (Fig. 1A)
Of the 200 consecutive patients who received a diagnosis
of BM, we excluded 22 patients who did not have ER,
PgR, or HER2 IHC data available. An additional 7
patients whose clinical data were incomplete were ex-
cluded, leaving a final cohort of 171 patients. Of these,
39 patients were HR positive (defined as ER positive
and/or PgR positive and HER2 negative), 55 were
TNBC (defined as ER negative, PgR negative, and
HER2 negative), and 77 were HER2 positive (38 HR
positive and 39 HR negative).
Patient Characteristics and Overall Outcomes Between
the Training Set and the Validation Set
Table 1 shows a comparison of the characteristics of the
patients between training and validation set. The median
age was not different (47 vs. 49; P ¼ .332 by
Mann-Whiney test). More patients with good PS (KPS,
70–100) were in the training set than were in the valida-
tion set, but the difference was not statistically significant
(67.8% vs. 58.3%; P ¼ .067). The subtype distributions
were also similar (HR-positive/HER2-negative, 22.8%
vs. 29.1%; HR-positive/HER2-positive, 22.2% vs.
21.1%; HR-negative/HER2-positive, 22.8% vs. 19.6%;
TN, 32.2% vs. 30.2%; P ¼ .865). The status of extra-
cranial systemic disease at the time of diagnosis was
not different (33.9% vs. 30.7% for controlled disease;
P ¼ .506). The percentages of trastuzumab treatment
for MBC were also not different (64.9% vs. 67.9%;
P ¼ .738).
Treatment Modalities After Diagnosis of BM in 171
Patients in the Training Set
A total of 168 patients (98.2%) were treated with
WBRT. Fifty-nine patients (34.5%) received surgical re-
section or stereotactic radiosurgery with or without
WBRT, and 110 patients (64.3%) received WBRT
only. For patients who have ≤3 lesions of BM (22 pa-
tients, 12.9%), we initially performed stereotactic radio-
surgery and performed WBRT when metastatic brain
lesions progress or new brain parenchymal lesion(s) de-
veloped. Seventy-five patients (43.9%) received systemic
chemotherapy after local control of brain metastatic
lesions with local modalities as surgery, SRS, and/or
WBRT. Of the HER2-positive patients, 65% of the pa-
tients received anti-HER2–directed therapy before BM
(Table 1).
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Assessment of Sperduto’s BC-Specific GPA
For our cohort, we calculated Sperduto’s BC-specific
GPA, which was published recently,17 and the GPA
score did not discriminate among prognostic classes in
our cohort. The BM-OSs for the GPA index were 6.0
months for class I (n ¼ 13), 10.1 months for class II
(n ¼ 48), 7.8 months for class III (n ¼ 47), and 11.1
months for class IV (n ¼ 51; P ¼ .283) (Fig. 1B). In ad-
dition, the prediction model for 1-year survival probabil-
ity of Sperduto’s BC-specific GPA had an AUC of 0.55 in
the training set (P ¼ .204) (Fig. 1C).
Multivariate Analysis of BM-OS
To develop a prognostic index with better predicting
power than previous ones, we performed a Cox-
regression multivariate analysis on BM-OS. Table 2
shows the independent risk factors for BM-OS in our
patient cohort. KPS, age ,70 years, HER2 positivity,
trastuzumab use for MBC before BM diagnosis, triple
negativity, and extracranial systemic disease control
were identified as independent risk factors for BM-OS
(hazard ratio [HR], 0.51 [P ¼ .0002] for KPS ≥70;
HR, 0.23 [P ¼ .002] for age ,70 years; HR, 2.06
[P ¼ .005] for HER2 positivity; HR, 0.54 [P ¼ .017]
for trastuzumab use; HR, 2.03 [P ¼ .002] for triple neg-
ativity; HR, 0.57 [P ¼ .002] for extracranial systemic
control).
Developing a Nomogram to Predict BM Outcomes and
External Validation
On the basis of the variables independently associated
with BM-OS from Cox-regression multivariate analysis,
we constructed a nomogram (Fig. 2A). The prediction
Fig. 1. (A) Training cohort. (B) BM-OS according to Sperduto’s GPA scoring system in training cohort, P ¼ .283. (C) ROC curve on
Sperduto’s GPA system to predict 1-year death in training set: AUC ¼ 0.55, P ¼ .204, 95% CI: 0.48–0.63.
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model for 1-year survival probability had an AUC of
0.73 in the training set (P, .0001) (Fig. 2B). In the val-
idation set, discriminations were good, with AUCs of
0.78 (P, .0001) (Fig. 2C). These results demonstrate
that the predictions for an independent data set were suf-
ficient, confirming the exportability of the model.
According to the nomogram scores, prognostic strat-
ification was performed. The BM-OSs for the nomogram
scores were 3.5 months for class I (nomogram score,
143–188; n ¼ 22); 6.5 months for class II (nomogram
score, 130–142; n ¼ 32), 10.6 months for class III (no-
mogram score, 88–129; n ¼ 46), and 14.0 months for
class IV (nomogram score, 42–87; n ¼ 71). The nomo-
gram scores significantly discriminated survival from
BM (P, .0001) (Fig. 2D). In addition, we validated
our nomogram model with an external patients’
cohort, and the BM-OS for each nomogram score was
calculated. The BM-OSs for the nomogram scores in
the validation set were 3.2 months for class I (nomogram
score, 143–188; n ¼ 63), 8.3 months for class II (nomo-
gram score, 130–142; n ¼ 34), 9.7 months for class III
(nomogram score, 88–129; n ¼ 48), and 15.3 months
for class IV (nomogram score, 42–87; n ¼ 47) for the
validation set (P, .0001) (Fig. 2E). This result demon-
strates excellent predictions in an independent data set
and, therefore, confirmed the exportability of the model.
A New Prognostic Model Based on the Analysis of
Nomogram Score to Predict BM-OS Using the Training
Patient Cohort
On the basis of our previous study,21 we analyzed sur-
vival from BM according to HER2 status and adminis-
tration of a trastuzumab treatment. In univariate
analysis, BM-OS was significantly different according
to HER2 status and trastuzumab therapy. The BM-OS
was 12.4 months in HER2-positive patients who had
received trastuzumab for MBC, followed by 8.6 months
in HER2-negative patients and 5.7 months in HER2-
positive patients who had not received trastuzumab
(P ¼ .026).
Next, we reviewed our nomogram scoring system
using a Cox-regression multivariate model for BM-OS.
We incorporated the status of trastuzumab use and ex-
tracranial systemic control into our new prognostic
model. Considering the nomogram score used to calcu-
late the hazard ratio for each variable, we assigned a
score according to the new GPA scoring system by ana-
lyzing nomogram scores for each factor: KPS (0 for KPS
,70 and 0.5 for KPS 70–100), age (0 for ≥70 years and
Table 1. Patients’ characteristics between the training set and the validation set
Patient characteristic Training set Validation set P value
Total number 171 199
Period 2000–2008 2004–2009
Age at BM
Median years (range) 47 (26–87) 49 (26–80) .332
≥70 y 5 (2.9%) 8 (4.0%) .778
,70 y 166 (97.1%) 191 (96.0%)
Performance status
KPS 70–100 116 (67.8%) 116 (58.3%) .067
KPS ,70 55 (32.2%) 83 (41.7%)
Subtype of tumor
ER+ and/or PgR+/HER22 39 (22.8%) 58 (29.1%) .865
ER+ and/or PgR+/HER2+ 38 (22.2%) 42 (21.1%)
ER2 and/or PgR2/HER2+ 39 (22.8%) 39 (19.6%)
ER2/PgR2/HER22 55 (32.2%) 60 (30.2%)
Extracranial systemic control at BM
Controlled (CR, PR, or SD) 58 (33.9%) 61 (30.7%) .506
Progression 113 (66.1%) 138 (69.3%)
Anti-HER2 treatment for metastatic BC before BM among HER2+ patients 50/77 (64.9%) 55/81 (67.9%) .738
Overall survival from BM (BM-OS)
Median months (range) 9.6 (0.1–88.3) 7.8 (0.1–57.8) .069
Abbreviations: BM, brain metastasis; KPS, Karnofsky performance status.
Table 2. Multivariate Cox-regression analysis on survival time
from brain metastasis to death
Hazard Ratio
(HR)
P value 95% CI
KPS ≥70 0.51 .0002 0.36–0.74
Age ,70 0.23 .002 0.09–0.60
HER2 positivity 2.06 .005 1.24–3.45
Trastuzumab use 0.54 .017 0.33–0.90
Triple negativity 2.03 .002 1.29–3.18
Extracranial disease control 0.57 .002 0.41–0.81
Abbreviations: KPS, Karnofsky performance status.
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Fig. 2. Nomogram to predict death from brain metastases (BM) in patients with BM from breast cancer (BC). (A) is nomogram. Points are
translated to probability of death. Predictor points are found on the upper-most point scale that corresponds with each patient variable. The
reader then manually adds up the points, and the predicted values can be read at the bottom of the nomogram. The total projected on the
bottom scale indicates the probability of death at 12 and 36-month. (B) showed ROC curve on nomogram to predict 1-year death in BM
breast cancers in training set. AUC ¼ 0.73, P, .0001, 95% CI: 0.65–0.79. (C) showed ROC curve on nomogram using external validation
set. AUC ¼ 0.78, P, .0001, 95% CI: 0.71–0.83. (Thin lines for each ROC curve represent 95% CI). (D) BM-OS according to nomogram
score in training set, P, .0001 by log-rank test. (E) BM-OS according to nomogram score in validation set, P, .001 by log-rank test.
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1.0 for ,70 years), hormone receptor status (0 for ER
negative and PgR negative and 0.5 for ER and/or PgR
positive), HER2 status (0 for HER2 positive without
trastuzumab, 0.5 for HER2 negative, 1.0 for HER2 pos-
itive with trastuzumab), extracranial disease control (0
for progressive disease and 0.5 for extracranial disease
control [at least stable disease]). Our new prognostic
model is displayed in Table 3. When survival analyses
were performed according to our modified prognostic
model, the BM-OS for each index was 3.7 months for
class I (n ¼ 15), 7.8 months for class II (n ¼ 82), 10.7
months for class III (n ¼ 42), and 19.2 months for
class IV (n ¼ 32; P, .0001) (Fig. 3A).
Validation of the New Prognostic Model in an External
Patient Cohort (n ¼ 199)
The new prognostic model score calculated for the vali-
dation set and the Kaplan-Meier survival curve distribu-
tion for each index are shown in Fig. 3B. The BM-OSs
for our modified GPA index were 2.5 months for class
I (n ¼ 42), 7.2 months for class II (n ¼ 57), 10.6
months for class III (n ¼ 61), and 13.1 months for
class IV (n ¼ 39) in the validation set. The newly
refined prognostic index model significantly discrimi-
nated survival among patients with BM from BC
(P, .0001) (Fig. 3B).
Discussion
An accurate prognostic system for patients with BM
from BC is urgently needed to appropriately select pa-
tients who would benefit from active and aggressive
treatment.7,8 Obviously, the type of treatment for BM
depends on several factors, including the patient’s neuro-
logical condition; extracranial systemic metastases; life
expectancy; number, size, and location of BM lesions;
and presence of leptomeningeal disease.22,23 However,
recent advances in our understanding of the biology un-
derlying BC have brought remarkable improvements to
systemic treatments for BC according to the intrinsic
Table 3. A new prognostic model for BM from breast cancer
New Prognostic Model
Raw score 0 0.5 1.0
KPS ,70 70–100
Age ≥70 ,70
ER/PgR ER-negative & PgR-negative ER &/or PgR-positive
HER2 HER2-positive w/o trastuzumab HER2-negative HER2-positive with trastuzumab
Extracranial disease control No Yes
Abbreviation: KPS, Karnofsky performance status; w/o, without.
Extracranial disease control: ≥SD (CR + PR + SD) of extracranial diseases at the time of diagnosis of BM.
aTotal score for each case is calculated by sum of raw scores for each variable (KPS, age, ER/PgR, HER2, extracranial disease control):
Class I; 0.5–1.0, Class II; 1.5–2.0, Class III; 2.5, Class IV; 3.0-3.5.
Fig. 3. Kaplan–Meier Survival curves from BM according to new proposed BC-specific GPA scoring system. (A) BM-OS according new
proposed BC-specific GPA score in training set, P, .0001 by log-rank test. (B) BM-OS according new proposed BC-specific GPA score
in validation set, P, .001 by log-rank test.
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subtypes.24,25 Furthermore, the most prominent studies
to date are primarily concerned with the biology of
each metastatic organ, such as brain, lung, and
bone.14,15,26–28 Therefore, harmonized disease control
for extracranial systemic disease and CNS lesion(s) of
each subtype may help indicate the proper treatment
options in each clinical setting. Accordingly, the recently
published Sperduto’s BC-specific GPA is the first
BC-specific prognostic score for patients with BM that
includes tumor biology and is timely and seems to be ap-
propriate. Therefore, we tried to validate Sperduto’s
BC-specific GPA, which was based on 400 patients in-
corporating KPS, ER/PR/HER2 status, and age.
However, it does not include trastuzumab use, which
improves BM-OS and changes the natural course of
HER2-positive BC. In addition to this, the scoring
system still needs to be validated, even though it has
been composed of a large number of prospective
cohorts. Their classification of BC included approxi-
mately 4 subtypes: basal (TN), luminal A (HER2 nega-
tive, HR positive), luminal B (HER2 positive, HR
positive), and HER2 (HER2 positive, HR negative).
This classification may represent intrinsic subtype
using immunohistochemistry. However, according to
the scoring system, the patients with HR-positive/
HER2-positive (called “luminal B”) appeared to have
better outcomes than those with HR-positive/
HER2-negative (called “luminal A”).17,29 These may
contribute to the inability to discriminate our patient
cohort into prognostic groups. Therefore, we developed
a nomogram to predict outcomes and used it to propose
a new prognostic model (Fig. 2A). However, it would
be better to develop more concise prognostic model for
use in daily clinical practice, because nomogram seems
to be complex to adapt and has to be calculated accord-
ing to the figure for each case. For this reason, we de-
veloped the new BC-specific GPA model incorporated
with the nomogram and validated excellently with
an external validation cohort from 2 institutes for the
same period.
The advantage of our nomogram (Fig. 2A) and the
new BC-GPA model (Table 3) is that we integrated
current treatment strategy and changes in disease
course according to biologic subtype of BC. In other
words, better extracranial systemic disease control after
introduction of trastuzumab affects the policy for local
control of BM. It does not result in a reduced role of sys-
temic treatment but places the emphasis on more active
systemic control and better local control. Our new
BC-specific GPA could be updated in the near future to
reflect the incorporation of the most current therapeutic
strategies. Paradoxically, our finding is supported by the
fact that TNBCs, which lack a properly targeted systemic
treatment, have the worst prognosis, and that most of the
deaths are associated with uncontrolled progression of
systemic diseases rather than from deterioration of BM
(data not shown).
Actually, Cox-regression multivariate analysis for
BM-OS in our patient cohort did not find number of
BM lesions as an independent prognostic factor.
Instead, intrinsic subtype, use of trastuzumab, and extra-
cranial systemic control were significant. This implies
that the interactions between underlying biological
factors and status of systemic disease control may have
a critical role in determining tumor behavior and out-
comes. Despite these strengths of the study, this is a ret-
rospective analysis with inherent selection bias. A variety
of treatment modalities had been applied during the long
period (2000–2008), which implies that a lot of changes
in the treatment of patients with BM from BC had oc-
curred in terms of local modalities and imaging
methods to monitor. These confounding variables may
result in unacceptable results. This is the main weakness
of this study.
In conclusion, we established a new prognostic model
to predict BM-OS by refining the Sperduto’s BC-specific
GPA index through the analysis of a nomogram and
through the incorporation of unique biological feature
of BCs. This new model would be a valuable tool for de-
signing innovative clinical trials and for decision making
in daily clinical practice. Further prospective study is
warranted.
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